Trials / Terminated
TerminatedNCT02393248
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 201 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).
Conditions
- Lung Cancer
- Solid Tumor
- Gastric Cancer
- Urothelial Cancer
- Endometrial Cancer
- Multiple Myeloma
- Myeloproliferative Neoplasms
- Breast Cancer
- Cholangiocarcinoma
- UC
- MPN
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemigatinib | |
| DRUG | Gemcitabine | |
| DRUG | Pembrolizumab | |
| DRUG | Docetaxel | |
| DRUG | Trastuzumab | |
| DRUG | Retifanlimab | |
| DRUG | Cisplatin |
Timeline
- Start date
- 2015-02-27
- Primary completion
- 2021-12-17
- Completion
- 2021-12-17
- First posted
- 2015-03-19
- Last updated
- 2023-01-06
- Results posted
- 2023-01-06
Locations
20 sites across 2 countries: United States, Denmark
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02393248. Inclusion in this directory is not an endorsement.